Antisense oligonucleotide therapy for TTR amyloidosis

Merrill Benson, S. Pandey, Rafat Abonour, A. Jazayeri, A. Siwkowski, B. Monia, B. Kluve-Beckerman

Research output: Contribution to journalArticle

Abstract

Orthotopic liver transplantation (OLT) that eliminates hepatic production of variant transthyretin (TTR) in patients with hereditary TTR amyloidosis is the only specific therapy that has been shown to be effective. Unfortunately, OLT does not stop progression of the disease in some patients since normal TTR can continue to be deposited as amyloid fibrils. In the present study, we have advanced in our attempts to develop a specific antisense oligonucleotide that will suppress hepatic production of TTR. With favorable response in TTR transgenic mice, studies have progressed to safety analysis in non-human primates.

Original languageEnglish
Pages (from-to)60
Number of pages1
JournalAmyloid
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Antisense oligonucleotide therapy for TTR amyloidosis'. Together they form a unique fingerprint.

  • Cite this

    Benson, M., Pandey, S., Abonour, R., Jazayeri, A., Siwkowski, A., Monia, B., & Kluve-Beckerman, B. (2011). Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid, 18(SUPPL. 1), 60. https://doi.org/10.3109/13506129.2011.574354